The two faces of the pharmacological interaction of mGlu2 and 5-HT2A-Relevance of receptor heterocomplexes and interaction through functional brain pathways

Neuropharmacology

Volumn 70, Issue , 2013, Pages 296-305

  Delille, Hannah K ^a   Mezler, Mario ^b   Marek, Gerard J ^b  

^a ABBOTT GMBH AND CO KG   (Germany)

^b ABBVIE INC   (United States)

Author keywords

5 Hydroxytryptamine receptor 2A (5 HT2A); Functional receptor interaction; G protein coupled receptor; GPCR; Heteromerization; Metabotropic glutamate receptor 2 (mGlu2); Receptor cross talk; Schizophrenia

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; CLOZAPINE; DIZOCILPINE; EGLUMETAD; G PROTEIN COUPLED RECEPTOR; KETANSERIN; LISURIDE; LY 459477; LY 487379; METABOTROPIC RECEPTOR 2; METHYSERGIDE; MG S0039; MIANSERIN; POMAGLUMETAD METHIONIL; PSYCHEDELIC AGENT; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; VOLINANSERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; BINDING AFFINITY; BINDING SITE; COMPLEX FORMATION; CONTROLLED STUDY; DIMERIZATION; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; EXCITATORY POSTSYNAPTIC POTENTIAL; HUMAN; LOCOMOTION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; HALLUCINOGENS; HUMANS; PROTEIN MULTIMERIZATION; RECEPTOR AGGREGATION; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; SEROTONIN 5-HT2 RECEPTOR AGONISTS;

EID: 84876986048     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.02.005     Document Type: Review

References (90)

1. G.K. Aghajanian, and G.J. Marek Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells Neuropharmacology 36 1997 589 599
2. G.K. Aghajanian, and G.J. Marek Serotonin and hallucinogens Neuropsychopharmacology 21 1999 16S 23S
3. G.K. Aghajanian, and G.J. Marek Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release Brain Res. 825 1999 161 171
4. L. Albizu, M. Cottet, M. Kralikova, S. Stoev, R. Seyer, I. Brabet, T. Roux, H. Bazin, E. Bourrier, L. Lamarque, C. Breton, M.L. Rives, A. Newman, J. Javitch, E. Trinquet, M. Manning, J.P. Pin, B. Mouillac, and T. Durroux Time-resolved FRET between GPCR ligands reveals oligomers in native tissues Nat. Chem. Biol. 6 2010 587 594
5. J.C. Beique, M. Imad, L. Mladenovic, J.A. Gingrich, and R. Andrade Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex Proc. Natl. Acad. Sci. U. S. A. 104 2007 9870 9875
6. M.A. Benneyworth, Z. Xiang, R.L. Smith, E.E. Garcia, P.J. Conn, and E. Sanders-Bush A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis Mol. Pharmacol. 72 2007 477 484
7. A. Bhatnagar, D.L. Willins, J.A. Gray, J. Woods, J.L. Benovic, and B.L. Roth The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis J. Biol. Chem. 276 2001 8269 8277
8. M. Bubser, J.R. Backstrom, E. Sanders-Bush, B.L. Roth, and A.Y. Deutch Distribution of serotonin 5-HT(2A) receptors in afferents of the rat striatum Synapse 39 2001 297 304
9. A. Carlsson, and M. Lindqvist Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain Acta Pharmacol. Toxicol. (Copenh) 20 1963 140 144
10. A.M. Catafau, M. Suarez, S. Bullich, J. Llop, G. Nucci, R.N. Gunn, C. Brittain, and M. Laruelle Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]raclopride PET Neuroimage 46 2009 447 458
11. J.T. Coyle Glutamate and schizophrenia: beyond the dopamine hypothesis Cell. Mol. Neurobiol. 26 2006 365 384
12. I. Creese, D.R. Burt, and S.H. Snyder Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 192 1976 481 483
13. J.M. Crook, M. Akil, B.C. Law, T.M. Hyde, and J.E. Kleinman Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects Mol. Psychiatry 7 2002 157 164
14. D. Cussac, E. Boutet-Robinet, M.C. Ailhaud, A. Newman-Tancredi, J.C. Martel, N. Danty, and I. Rauly-Lestienne Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells Eur. J. Pharmacol. 594 2008 32 38
15. J.M. Davis, N. Chen, and I.D. Glick A meta-analysis of the efficacy of second-generation antipsychotics Arch. Gen. Psychiatry 60 2003 553 564
16. J. de Almeida, and G. Mengod Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT(2A) receptors in human and monkey prefrontal cortex J. Neurochem. 103 2007 475 486
17. B. Dean The cortical serotonin 2A receptor and the pathology of schizophrenia: a likely accomplice J. Neurochem. 85 2003 1 13
18. H.K. Delille, J.M. Becker, S. Burkhardt, B. Bleher, G.C. Terstappen, M. Schmidt, A.H. Meyer, L. Unger, G.J. Marek, and M. Mezler Heterocomplex formation of 5-HT(2A)-mGlu(2) and its relevance for cellular signaling cascades Neuropharmacology 62 2012 2183 2190
19. E. Doumazane, P. Scholler, J.M. Zwier, E. Trinquet, P. Rondard, and J.P. Pin A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors FASEB J. 25 1 2011 66 77
20. J. Dragavon, S. Blazquez, A. Rekiki, C. Samson, I. Theodorou, K.L. Rogers, R. Tournebize, and S.L. Shorte In vivo excitation of nanoparticles using luminescent bacteria Proc. Natl. Acad. Sci. U. S. A. 109 2012 8890 8895
21. D. Erritzoe, H. Rasmussen, K.T. Kristiansen, V.G. Frokjaer, S. Haugbol, L. Pinborg, W. Baare, C. Svarer, J. Madsen, H. Lublin, G.M. Knudsen, and B.Y. Glenthoj Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients Neuropsychopharmacology 33 2008 2435 2441
22. M.J. Fell, K.W. Perry, J.F. Falcone, B.G. Johnson, V.N. Barth, K.S. Rash, V.L. Lucaites, P.G. Threlkeld, J.A. Monn, D.L. McKinzie, G.J. Marek, K.A. Svensson, and D.L. Nelson In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6- dicarboxylic acid (LY379268) J. Pharmacol. Exp. Ther. 331 2009 1126 1136
23. M.J. Fell, K.A. Svensson, B.G. Johnson, and D.D. Schoepp Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4- amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039) J. Pharmacol. Exp. Ther. 326 2008 209 217
24. M. Fribourg, J.L. Moreno, T. Holloway, D. Provasi, L. Baki, R. Mahajan, G. Park, S.K. Adney, C. Hatcher, J.M. Eltit, J.D. Ruta, L. Albizu, Z. Li, A. Umali, J. Shim, A. Fabiato, A.D. Mackerell Jr., V. Brezina, S.C. Sealfon, M. Filizola, J. Gonzalez-Maeso, and D.E. Logothetis Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs Cell 147 2011 1011 1023
25. J.C. Gewirtz, A.C. Chen, R. Terwilliger, R.C. Duman, and G.J. Marek Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors Pharmacol. Biochem. Behav. 73 2002 317 326
26. J.C. Gewirtz, and G.J. Marek Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors Neuropsychopharmacology 23 2000 569 576
27. S. Ghose, J.M. Crook, C.L. Bartus, T.G. Sherman, M.M. Herman, T.M. Hyde, J.E. Kleinman, and M. Akil Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia Int. J. Neurosci. 118 2008 1609 1627
28. S. Ghose, K.A. Gleason, B.W. Potts, K. Lewis-Amezcua, and C.A. Tamminga Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am. J. Psychiatry 166 2009 812 820
29. J. Gonzalez-Maeso, R.L. Ang, T. Yuen, P. Chan, N.V. Weisstaub, J.F. Lopez-Gimenez, M. Zhou, Y. Okawa, L.F. Callado, G. Milligan, J.A. Gingrich, M. Filizola, J.J. Meana, and S.C. Sealfon Identification of a serotonin/glutamate receptor complex implicated in psychosis Nature 452 2008 93 97
30. J. Gonzalez-Maeso, N.V. Weisstaub, M. Zhou, P. Chan, L. Ivic, R. Ang, A. Lira, M. Bradley-Moore, Y. Ge, Q. Zhou, S.C. Sealfon, and J.A. Gingrich Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior Neuron 53 2007 439 452
31. J. Gonzalez-Maeso, T. Yuen, B.J. Ebersole, E. Wurmbach, A. Lira, M. Zhou, N. Weisstaub, R. Hen, J.A. Gingrich, and S.C. Sealfon Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex J. Neurosci. 23 2003 8836 8843
32. J. Gonzalez-Maeso, and S.C. Sealfon Psychedelics and schizophrenia Trends Neurosci. 32 4 2009 225 232
33. E. Gouzoulis-Mayfrank, K. Heekeren, A. Neukirch, M. Stoll, C. Stock, M. Obradovic, and K.A. Kovar Psychological effects of (S)-ketamine and N, N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers Pharmacopsychiatry 38 2005 301 311
34. D.S. Gupta, R.E. McCullumsmith, M. Beneyto, V. Haroutunian, K.L. Davis, and J.H. Meador-Woodruff Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia Synapse 57 2005 123 131
35. O.D. Howes, J. Kambeitz, E. Kim, D. Stahl, M. Slifstein, A. Abi-Dargham, and S. Kapur The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies Arch. Gen. Psychiatry 69 2012 776 786
36. R.L. Jakab, and P.S. Goldman-Rakic 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites Proc. Natl. Acad. Sci. U. S. A. 95 1998 735 740
37. J.H. Kehne, B.M. Baron, A.A. Carr, S.F. Chaney, J. Elands, D.J. Feldman, R.A. Frank, P.L. van Giersbergen, T.C. McCloskey, M.P. Johnson, D.R. McCarty, M. Poirot, Y. Senyah, B.W. Siegel, and C. Widmaier Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile J. Pharmacol. Exp. Ther. 277 1996 968 981
38. A. Kern, R. Albarran-Zeckler, H.E. Walsh, and R.G. Smith Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism Neuron 73 2012 317 332
39. G. Khelashvili, K. Dorff, J. Shan, M. Camacho-Artacho, L. Skrabanek, B. Vroling, M. Bouvier, L.A. Devi, S.R. George, J.A. Javitch, M.J. Lohse, G. Milligan, R.R. Neubig, K. Palczewski, M. Parmentier, J.P. Pin, G. Vriend, F. Campagne, and M. Filizola GPCR-OKB: the G Protein coupled receptor oligomer knowledge base Bioinformatics 26 2010 1804 1805
40. E. Klieser, and W.H. Strauss Study to establish the indication for the selective S2 antagonist ritanserin Pharmacopsychiatry 21 1988 391 393
41. A. Klodzinska, M. Bijak, K. Tokarski, and A. Pilc Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice Pharmacol. Biochem. Behav. 73 2002 327 332
42. E.K. Lambe, and G.K. Aghajanian The role of Kv1.2-containing potassium channels in serotonin-induced glutamate release from thalamocortical terminals in rat frontal cortex J. Neurosci. 21 2001 9955 9963
43. E.K. Lambe, and G.K. Aghajanian Hypocretin (orexin) induces calcium transients in single spines postsynaptic to identified thalamocortical boutons in prefrontal slice Neuron 40 2003 139 150
44. M. Laruelle, A. Abi-Dargham, M.F. Casanova, R. Toti, D.R. Weinberger, and J.E. Kleinman Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study Arch. Gen. Psychiatry 50 1993 810 818
45. C. Lebrand, O. Cases, R. Wehrle, R.D. Blakely, R.H. Edwards, and P. Gaspar Transient developmental expression of monoamine transporters in the rodent forebrain J. Comp. Neurol. 401 1998 506 524
46. R. Lewis, S. Kapur, C. Jones, J. DaSilva, G.M. Brown, A.A. Wilson, S. Houle, and R.B. Zipursky Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects Am. J. Psychiatry 156 1999 72 78
47. A.M. Linden, B.G. Johnson, N. Trokovic, E.R. Korpi, and D.D. Schoepp Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495 Neuropharmacology 57 2009 172 182
48. K. Majak, P. Kowianski, J. Morys, J. Spodnik, Z. Karwacki, and H.M. Wisniewski The limbic zone of the rabbit and rat claustrum: a study of the claustrocingulate connections based on the retrograde axonal transport of fluorescent tracers Anat. Embryol. (Berl) 201 2000 15 25
49. S.R. Marder Limitations of dopamine-D2 antagonists and the search for novel antipsychotic strategies Neuropsychopharmacology 21 1999 S117 S121
50. G.J. Marek, and G.K. Aghajanian LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex J. Pharmacol. Exp. Ther. 278 1996 1373 1382
51. G.J. Marek, and G.K. Aghajanian 5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by mu-opiate receptor activation Neuroscience 86 1998 485 497
52. G.J. Marek, B.J. Kinon, D.L. McKinzie, J.M. Schkeryantz, and J.A. Monn Metabotropic glutamate 2/3 receptor agonists and positive allosteric modulators of metabotropic glutamate receptor 2 as novel agents for the treatment of schizophrenia J.S. Albert, M.W. Wood, Targets and Emerging Therapies for Schizophrenia 2012 John Wiley & Sons, Inc. 143 185
53. G.J. Marek, R.A. Wright, J.C. Gewirtz, and D.D. Schoepp A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex Neuroscience 105 2001 379 392
54. G.J. Marek, R.A. Wright, D.D. Schoepp, J.A. Monn, and G.K. Aghajanian Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex J. Pharmacol. Exp. Ther. 292 2000 76 87
55. G.J. Marek, and C. Zhang Activation of metabotropic glutamate 5 (mGlu5) receptors induces spontaneous excitatory synaptic currents in layer V pyramidal cells of the rat prefrontal cortex Neurosci. Lett. 442 2008 239 243
56. B.N. Mathur, R.M. Caprioli, and A.Y. Deutch Proteomic analysis illuminates a novel structural definition of the claustrum and insula Cereb. Cortex 19 2009 2372 2379
57. I. Matsumoto, Y. Inoue, T. Iwazaki, G. Pavey, and B. Dean 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study Neurosci. Lett. 379 2005 164 168
58. H.Y. Meltzer, L. Arvanitis, D. Bauer, and W. Rein Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder Am. J. Psychiatry 161 2004 975 984
59. H.Y. Meltzer, S. Matsubara, and J.C. Lee Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values J. Pharmacol. Exp. Ther. 251 1989 238 246
60. L.A. Miner, J.R. Backstrom, E. Sanders-Bush, and S.R. Sesack Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex Neuroscience 116 2003 107 117
61. B. Moghaddam, and B.W. Adams Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats Science 281 1998 1349 1352
62. J.L. Moreno, T. Holloway, L. Albizu, S.C. Sealfon, and J. Gonzalez-Maeso Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists Neurosci. Lett. 493 2011 76 79
63. R.R. Neubig, M. Spedding, T. Kenakin, and A. Christopoulos International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology Pharmacol. Rev. 55 2003 597 606
64. E.T. Ngan, L.N. Yatham, T.J. Ruth, and P.F. Liddle Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [(18)F]setoperone Am. J. Psychiatry 157 2000 1016 1018
65. Y. Okubo, T. Suhara, K. Suzuki, K. Kobayashi, O. Inoue, O. Terasaki, Y. Someya, T. Sassa, Y. Sudo, E. Matsushima, M. Iyo, Y. Tateno, and M. Toru Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography Life Sci. 66 2000 2455 2464
66. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, B.V. Andreev, A.S. Avedisova, L.M. Bardenstein, I.Y. Gurovich, M.A. Morozova, S.N. Mosolov, N.G. Neznanov, A.M. Reznik, A.B. Smulevich, V.A. Tochilov, B.G. Johnson, J.A. Monn, and D.D. Schoepp Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial Nat.Med 13 2007 1102 1107
67. J.P. Pin, R. Neubig, M. Bouvier, L. Devi, M. Filizola, J.A. Javitch, M.J. Lohse, G. Milligan, K. Palczewski, M. Parmentier, and M. Spedding International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers Pharmacol. Rev. 59 2007 5 13
68. R.H. Porter, K.R. Benwell, H. Lamb, C.S. Malcolm, N.H. Allen, D.F. Revell, D.R. Adams, and M.J. Sheardown Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells Br. J. Pharmacol. 128 1999 13 20
69. J.C. Rekling NK-3 receptor activation depolarizes and induces an after-depolarization in pyramidal neurons in gerbil cingulate cortex Brain Res. Bull. 63 2004 85 90
70. N. Santana, A. Bortolozzi, J. Serrats, G. Mengod, and F. Artigas Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex Cereb. Cortex 14 2004 1100 1109
71. J.L. Scruggs, S. Patel, M. Bubser, and A.Y. Deutch DOI-Induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons J. Neurosci. 20 2000 8846 8852
72. P. Seeman, T. Lee, M. Chau-Wong, and K. Wong Antipsychotic drug doses and neuroleptic/dopamine receptors Nature 261 1976 717 719
73. S.M. Sherman, and R.W. Guillery Exploring the Thalamus and Its Role in Cortical Function 2006 MIT Press Cambridge, MA
74. J.K. Shirey, A.E. Brady, P.J. Jones, A.A. Davis, T.M. Bridges, J.P. Kennedy, S.B. Jadhav, U.N. Menon, Z. Xiang, M.L. Watson, E.P. Christian, J.J. Doherty, M.C. Quirk, D.H. Snyder, J.J. Lah, A.I. Levey, M.M. Nicolle, C.W. Lindsley, and P.J. Conn A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning J. Neurosci. 29 2009 14271 14286
75. L. Skrabanek, M. Murcia, M. Bouvier, L. Devi, S.R. George, M.J. Lohse, G. Milligan, R. Neubig, K. Palczewski, M. Parmentier, J.P. Pin, G. Vriend, J.A. Javitch, F. Campagne, and M. Filizola Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base BMC Bioinform. 8 2007 177
76. W.P. Spooren, F. Gasparini, P.H. van der, M. Koller, S. Nakanishi, and R. Kuhn Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice Eur. J. Pharmacol. 397 2000 R1 R2
77. G.E. Stutzmann, G.J. Marek, and G.K. Aghajanian Adenosine preferentially suppresses serotonin2A receptor-enhanced excitatory postsynaptic currents in layer V neurons of the rat medial prefrontal cortex Neuroscience 105 2001 55 69
78. C. Trichard, M.L. Paillere-Martinot, D. Attar-Levy, J. Blin, A. Feline, and J.L. Martinot No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET Schizophr. Res. 31 1998 13 17
79. V.A. Vaidya, G.J. Marek, G.K. Aghajanian, and R.S. Duman 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex J. Neurosci. 17 1997 2785 2795
80. E.T. Weber, and R. Andrade Htr2a gene and 5-HT(2A) receptor expression in the cerebral cortex studied using genetically modified mice Front. Neurosci. 4 2010
81. N.V. Weisstaub, M. Zhou, A. Lira, E. Lambe, J. Gonzalez-Maeso, J.P. Hornung, E. Sibille, M. Underwood, S. Itohara, W.T. Dauer, M.S. Ansorge, E. Morelli, J.J. Mann, M. Toth, G. Aghajanian, S.C. Sealfon, R. Hen, and J.A. Gingrich Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice Science 313 2006 536 540
82. D.L. Willins, S.A. Berry, L. Alsayegh, J.R. Backstrom, E. Sanders-Bush, L. Friedman, and B.L. Roth Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo Neuroscience 91 1999 599 606
83. J.C. Winter, J.R. Eckler, and R.A. Rabin Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli Psychopharmacology (Berl) 172 2004 233 240
84. L. Wischhof, and M. Koch Pre-treatment with the mGlu2/3 receptor agonist LY379268 attenuates DOI-induced impulsive responding and regional c-Fos protein expression Psychopharmacology (Berl) 219 2012 387 400
85. M.L. Woolley, D.J. Pemberton, S. Bate, C. Corti, and D.N. Jones The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity Psychopharmacology (Berl) 196 2008 431 440
86. R.A. Wright, M.B. Arnold, W.J. Wheeler, P.L. Ornstein, and D.D. Schoepp [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain J. Pharmacol. Exp. Ther. 298 2001 453 460
87. R.A. Wright, B.G. Johnson, C. Zhang, C. Salhoff, A.E. Kingston, D.O. Calligaro, J.A. Monn, D.D. Schoepp, and G.J. Marek CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [(3)H]LY459477 autoradiography Neuropharmacology 66 2013 89 98
88. R.A. Wright, and D.D. Schoepp Effect of Chronic Exposure to MGlu2/3 Receptor Ligands (LY354740, LY379268 or LY341495) or Antipsychotic Agents Clozapine or Haloperidol on Binding to MGlu2/3 and 5-HT2A Receptors in Rat Prelimbic Cortex Neuroscience Meeting Planner 2003 Society for Neuroscience New Orleans, LA
89. Y. Zhai, C.A. George, J. Zhai, E.S. Nisenbaum, M.P. Johnson, and L.K. Nisenbaum Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex Neuropsychopharmacology 28 2003 45 52
90. C. Zhang, and G.J. Marek Group III metabotropic glutamate receptor agonists selectively suppress excitatory synaptic currents in the rat prefrontal cortex induced by 5-hydroxytryptamine2A receptor activation J. Pharmacol. Exp. Ther. 320 2007 437 447